Phase 3 Recruiting Academic/Other
This phase III trial compares the effect of adding stereotactic body radiation therapy (SBRT) to the usual treatment (conventional image guided radiation therapy \[IGRT\] and chemotherapy followed by immunotherapy with durvalumab or target…
Sponsor: NRG Oncology
NCT ID: NCT05624996
Sites in North Carolina: - Atrium Health Stanly/LCI-Albemarle — Albemarle, North Carolina
- Duke Cancer Center Cary — Cary, North Carolina
- UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
- Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Novant Health Presbyterian Medical Center — Charlotte, North Carolina
Phase 3 Recruiting Industry
This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-sm…
Sponsor: Pfizer
NCT ID: NCT07222566
Sites in North Carolina: - FirstHealth Cancer Center — Pinehurst, North Carolina
- FirstHealth Moore Regional Hospital — Pinehurst, North Carolina
- Carolina Cancer Research Center — Wilson, North Carolina
Phase 3 Recruiting Industry
The purpose of the study is to compare how the new combination treatment (Sigvotatug Vedotin plus pembrolizumab) works compared to pembrolizumab alone in patients with non-small cell lung cancer (NSCLC) with high levels of PD-L1. This is a…
Sponsor: Pfizer
NCT ID: NCT06758401
Sites in North Carolina: - Brody School of Medicine at East Carolina University — Greenville, North Carolina
- ECU Health Medical Center — Greenville, North Carolina
- Carolina Cancer Research Center — Wilson, North Carolina
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in North Carolina: - Research Site — Wilson, North Carolina
Phase 3 Recruiting NIH
This phase III trial compares the effect of atezolizumab (or atezolizumab and recombinant human hyaluronidase) to standard observation for preventing cancer return after surgery (recurrence) in patients who have undergone a complete surgic…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT07388524
Sites in North Carolina: - FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced o…
Sponsor: AstraZeneca
NCT ID: NCT06357533
Sites in North Carolina: - Research Site — Greenville, North Carolina
- Research Site — Salisbury, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy and safety of divarasib and pembrolizumab compared with pembrolizumab and pemetrexed and carboplatin or cisplatin, for the first-line treatment of adult participants with KRAS G12C-muta…
Sponsor: Hoffmann-La Roche
NCT ID: NCT06793215
Sites in North Carolina: - Firsthealth of The Carolinas — Pinehurst, North Carolina
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in North Carolina: - Fletcher Hospital, Inc. dba AdventHealth Hendersonville — Hendersonville, North Carolina
Phase 3 Recruiting Industry
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene a…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06623422
Sites in North Carolina: - Novant Health Weisiger Cancer Insititute ( Site 0266) — Charlotte, North Carolina
- Novant Health Forsyth Medical Center ( Site 0166) — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
This is a trial to evaluate the efficacy, safety, and tolerability of adagrasib plus pembrolizumab plus platinum-doublet chemotherapy versus placebo plus pembrolizumab plus platinum-doublet chemotherapy in participants with previously untr…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT06875310
Sites in North Carolina: - Local Institution - 0624 — Asheville, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the efficacy of Pumitamig versus Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%.
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07361510
Sites in North Carolina: - Novant Health Pharmacy Oncology Specialists — Winston-Salem, North Carolina
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in North Carolina: - University of North Carolina — Chapel Hill, North Carolina
- Wake Forest Baptist Health — Winston-Salem, North Carolina
Phase 3 Recruiting Industry
Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sites including mediastinal lymph nodes, liver, bones, adrenal glands, and brain. The purpose of this study is …
Sponsor: AbbVie
NCT ID: NCT07365241
Sites in North Carolina: - FirstHealth of the Carolinas- Speciality Center /ID# 279857 — Pinehurst, North Carolina
Phase 3 Recruiting Industry
This study, known as LUNAR-2, aims to investigate the effectiveness and safety of using TTFields, delivered by the NovoTTF-200T device, concomitantly administered with pembrolizumab and platinum-based chemotherapy for patients with advance…
Sponsor: NovoCure GmbH
NCT ID: NCT06216301
Sites in North Carolina: - WakeMed Health & Hospitals — Cary, North Carolina
Phase 3 Recruiting Industry
Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose t…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07195695
Sites in North Carolina: - Levine Cancer Institute — Charlotte, North Carolina
- Durham VA Health Care System — Durham, North Carolina
Phase 3 Recruiting Industry
This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu®) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no pr…
Sponsor: Daiichi Sankyo
NCT ID: NCT06899126
Sites in North Carolina: - FirstHealth Cancer Center — Pinehurst, North Carolina
- Carolina Cancer Research Center — Wilson, North Carolina
Phase 3 Recruiting Industry
Multicenter, randomized, controlled, open-label, Phase 3 study designed to demonstrate that neladalkib (NVL-655) is superior to alectinib in prolonging progression-free survival (PFS) in patients with treatment-naïve, Anaplastic Lymphoma K…
Sponsor: Nuvalent Inc.
NCT ID: NCT06765109
Sites in North Carolina: - Carolinas Medical Center — Charlotte, North Carolina
- Duke Cancer Center — Durham, North Carolina
Phase 3 Recruiting Industry
This is a randomized, two-cohort, open-label, phase 3, clinical trial to compare the efficacy and safety of N-803 plus tislelizumab and docetaxel (cohort A) or prior failed Health Authority-approved antiprogrammed death-1 (PD-1) or anti-pr…
Sponsor: ImmunityBio, Inc.
NCT ID: NCT06745908
Sites in North Carolina: - Carolina Oncology Specialists — Hickory, North Carolina
Phase 3 Recruiting Industry
This study is open to adults with advanced small cell lung cancer (SCLC). The purpose of this study is to find out if a study medicine called obrixtamig plus standard treatment (atezolizumab, carboplatin, and etoposide) improves survival w…
Sponsor: Boehringer Ingelheim
NCT ID: NCT07472517
Sites in North Carolina: - Cape Fear Valley Cancer Center — Fayetteville, North Carolina
Phase 3 Recruiting Industry
The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier opening with Exablate Model 4000 Type 2.0/2.1 for the treatment of NSCLC brain metastases in patients who are undergoing planned FDA approved,…
Sponsor: InSightec
NCT ID: NCT05317858
Sites in North Carolina: - Atrium Health Wake Forest Baptist — Winston-Salem, North Carolina
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in North Carolina: - FirstHealth of the Carolinas-Moore Regional Hospital — Pinehurst, North Carolina
Phase 2 Recruiting Academic/Other
This phase II trial compares the effect of intensity-modulated post-operative radiation therapy (I²-PORT) followed by standard of care therapy (chemotherapy or immunotherapy) to standard of care therapy alone in treating patients with non-…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT07293247
Sites in North Carolina: - UNC Lineberger Comprehensive Cancer Center — Chapel Hill, North Carolina
Phase 1, Phase 2 Recruiting NIH
This phase I/II trial tests the safety, side effects, and best dose of iadademstat when given together with atezolizumab or durvalumab, and studies the effect of the combination in treating patients with small cell lung cancer that has spr…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06287775
Sites in North Carolina: - Carolinas Medical Center/Levine Cancer Institute — Charlotte, North Carolina
- Atrium Health Cabarrus/LCI-Concord — Concord, North Carolina
- Wake Forest University Health Sciences — Winston-Salem, North Carolina
Phase 1, Phase 2 Recruiting Industry
The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. Th…
Sponsor: PMV Pharmaceuticals, Inc
NCT ID: NCT04585750
Sites in North Carolina: - Duke University — Durham, North Carolina
Phase 2 Recruiting Industry
The purpose of this study is to determine if treatment with a single dose of RE104 for Injection reduces depressive symptoms or depressive symptoms mixed with anxiety symptoms in participants with Adjustment Disorder due to cancer or other…
Sponsor: Reunion Neuroscience Inc
NCT ID: NCT07002034
Sites in North Carolina: - University of North Carolina at Chapel Hill — Chapel Hill, North Carolina